Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 30, 2025Current OncologyOpen Access

Real-World Prevalence, Treatment Patterns, and Economic Impact of EGFR- and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Analysis from Greece

View Full Paper
Ask AI
Bookmark
Share

Authors

GGGeorge GourzoulidisCKCatherine KastaniotiGMGeorge Mavridoglou

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals treatment patterns and the economic burden of EGFR and ALK therapies in NSCLC patients.

Key Points

  • A total of 1188 EGFR-positive and 246 ALK-positive patients began first-line treatment from 2020 to 2022.
  • Osimertinib usage in EGFR-positive patients rose from 41% in 2020 to 63% in 2022, indicating a significant shift in treatment preferences.
  • Annual drug expenditures for EGFR-related treatments remained stable at around €11.5 million to €11.9 million from 2020 to 2022.
  • This analysis highlights the substantial economic burden of targeted therapies, emphasizing the need for cost-effectiveness evaluations in healthcare.

Cite This Study

Gourzoulidis et al. (2025) studied this question.

synapsesocial.com/papers/68dc1e438a7d58c25ebb2348https://doi.org/10.3390/curroncol32100542
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer2025
  2. 2Real-world testing practices, treatment patterns, and outcomes of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor-mutated advanced/metastatic non-small cell lung cancer: An international study2026
  3. 3Real-World Clinical and Economic Consequences of Next-Generation Anaplastic Lymphoma Kinase-Positive (ALK +) Tyrosine Kinase Inhibitors (TKIs) in Patients with TKI-Naïve ALK + Metastatic Non-Small Cell Lung Cancer in the United States2026
  4. 4Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung Cancer2025 · 1 citations
  5. 5Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung Cancer2025 · 1 citations